神经重症监护病房静脉丙帕他莫诱导血压下降的危险因素:一项回顾性观察研究
该回顾性观察研究纳入2013年4月至2020年6月单家三级学术医院神经重症监护病房中连续接受静脉丙帕他莫给药的患者,共4916例患者、16586次给药。静脉丙帕他莫给药后收缩压较基线显著下降(基线131.1 ± 17.8 mm Hg,1小时内124.6 ± 17.3 mm Hg,1至2小时123.4 ± 17.4 mm Hg,P < 0.01),2小时内血压下降事件发生率为13.5%。多因素logistic回归显示高龄、基线收缩压较低或较高、发热、APACHE II评分较高、合用血管活性药/正性肌力药或镇痛镇静药是与血压下降事件显著相关的因素。作者认为,对具有上述危险因素、更易发生血流动力学变化的神经重症患者,应审慎使用静脉丙帕他莫。
要点
- 神经重症患者16586次静脉丙帕他莫给药后,2小时内血压下降事件发生率为13.5%(血压下降定义为收缩压低于90 mm Hg或较基线下降≥30 mm Hg)。
- 给药后收缩压较基线显著下降:基线131.1 ± 17.8 mm Hg,1小时内124.6 ± 17.3 mm Hg,1至2小时123.4 ± 17.4 mm Hg(P < 0.01)。
- 高龄、基线收缩压较低或较高、发热、APACHE II评分较高、合用血管活性药/正性肌力药或镇痛镇静药是血压下降事件的显著相关因素。
- 作者认为,对具有上述危险因素、更易发生血流动力学变化的神经重症患者,应审慎使用静脉丙帕他莫。
适用人群与场景
- 单家三级学术医院神经重症监护病房中2013年4月至2020年6月连续接受静脉丙帕他莫给药的患者,共4916例患者、16586次给药。
诊断标准与关键阈值
- 血压下降定义为收缩压低于90 mm Hg或收缩压下降30 mm Hg或以上。
- 血压、脉率和体温在基线和静脉丙帕他莫给药后2小时内采集。
研究设计与关键结果
- 研究类型:回顾性观察研究;单家三级学术医院神经重症监护病房;2013年4月至2020年6月连续接受静脉丙帕他莫给药的患者4916例,共16586次给药。
- 静脉丙帕他莫给药后收缩压显著下降:基线131.1 ± 17.8 mm Hg,1小时内124.6 ± 17.3 mm Hg,1至2小时123.4 ± 17.4 mm Hg(P < 0.01)。
- 静脉丙帕他莫给药后2小时内血压下降事件发生率为13.5%。
- 多因素logistic回归显示,高龄、基线收缩压较低或较高、发热、APACHE II评分较高、合用血管活性药/正性肌力药或镇痛镇静药是与血压下降事件显著相关的因素。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于本研究结果,对具有使其更易发生血流动力学变化的危险因素(高龄、基线收缩压较低或较高、发热、APACHE II评分较高、合用血管活性药/正性肌力药或镇痛镇静药)的神经重症患者,应审慎使用静脉丙帕他莫。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intravenous propacetamol is commonly used to control fever and pain in neurocritically ill patients in whom oral administration is often difficult. However, several studies reported that intravenous propacetamol may cause blood pressure drop. Thus, we aimed to investigate the occurrence and risk factors for intravenous propacetamol-induced blood pressure drop in neurocritically ill patients.
METHODS: This retrospective study included consecutive patients who were administered intravenous propacetamol in a neurointensive care unit at a single tertiary academic hospital between April 2013 and June 2020. The exact timing of intravenous propacetamol administration was collected from a database of the electronic barcode medication administration system. Blood pressure drop was defined as a systolic blood pressure below 90 mm Hg or a decrease by 30 mm Hg or more. Blood pressure, pulse rate, and body temperature were collected at baseline and within 2 h after intravenous propacetamol administration. The incidence of blood pressure drop was evaluated, and multivariable logistic regression analysis was performed to identify risk factors for blood pressure drop events.
RESULTS: A total of 16,586 instances of intravenous propacetamol administration in 4916 patients were eligible for this study. Intravenous propacetamol resulted in a significant decrease in systolic blood pressure (baseline 131.1 ± 17.8 mm Hg; within 1 h 124.6 ± 17.3 mm Hg; between 1 and 2 h 123.4 ± 17.4 mm Hg; P < 0.01). The incidence of blood pressure drop events was 13.5% within 2 h after intravenous propacetamol. Older age, lower or higher baseline systolic blood pressure, fever, higher Acute Physiology and Chronic Health Evaluation II score, and concomitant administration of vasopressors/inotropes or analgesics/sedatives were significant factors associated with the occurrence of blood pressure drop events after intravenous propacetamol administration.
CONCLUSIONS: Intravenous propacetamol can induce hemodynamic changes and blood pressure drop events in neurocritically ill patients. This study identified the risk factors for blood pressure drop events. On the basis of our results, judicious use of intravenous propacetamol is warranted for neurocritically ill patients with risk factors that make them more susceptible to hemodynamic changes.
参考来源
- Lee E, Song YJ, Jeon S, et al. Risk Factors for Intravenous Propacetamol-Induced Blood Pressure Drop in the Neurointensive Care Unit: A Retrospective Observational Study. Neurocrit Care. 2021. PMID: 34791593. doi:10.1007/s12028-021-01390-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。